Prognostic value and dynamics of antithyroglobulin antibodies for differentiated thyroid carcinoma

被引：13

作者：

Sun, Danyang ^{[1
,2
]}

Zheng, Xiangqian ^{[3
]}

He, Xianghui ^{[4
]}

Huang, Chao ^{[5
]}

Jia, Qiang ^{[2
]}

Tan, Jian ^{[2
]}

Zheng, Wei ^{[2
]}

Li, Ning ^{[2
]}

Wang, Peng ^{[2
]}

Wang, Renfei ^{[2
]}

Liu, Ming ^{[6
]}

Zhao, Li ^{[7
]}

Yuan, Shukai ^{[7
]}

Meng, Zhaowei ^{[1
,2
]}

Fan, Yaguang ^{[8
]}

机构：

[1] Tianjin Med Univ Gen Hosp Airport Site, Dept Nucl Med, Tianjin, Peoples R China

[2] Tianjin Med Univ Gen Hosp, Dept Nucl Med, Tianjin, Peoples R China

[3] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Thyroid & Neck Tumor, Key Lab Canc Prevent & Therapy Tianjin City, Tianjin, Peoples R China

[4] Tianjin Med Univ Gen Hosp, Dept Gen Surg, Tianjin, Peoples R China

[5] Univ Hull, Hull York Med Sch, Stat, Kingston Upon Hull, N Humberside, England

[6] Tianjin Med Univ Gen Hosp, Dept Endocrinol & Metab, Tianjin, Peoples R China

[7] Sch Basic Med Sci, Dept Biochem & Mol Biol, Tianjin, Peoples R China

[8] Tianjin Med Univ Gen Hosp, Tianjin Lung Canc Inst, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Tianjin, Peoples R China

来源：

BIOMARKERS IN MEDICINE | 2020年 / 14卷 / 18期

基金：

中国国家自然科学基金;

关键词：

I-131; therapy; antithyroglobulin antibody; differentiated thyroid cancer; half-life; thyroglobulin; SERUM THYROGLOBULIN ANTIBODY; MANAGEMENT GUIDELINES; CLINICAL-SIGNIFICANCE; NEGATIVE PATIENTS; CANCER; DISEASE; I-131; RECURRENCE; ABLATION; TGAB;

D O I：

10.2217/bmm-2019-0432

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background: The clinical value of antithyroglobulin antibodies (TgAb) as a tumor marker for differentiated thyroid cancer (DTC) is still controversial. Materials & methods: We studied 110 TgAb positive DTC patients who underwent total thyroidectomy and I-131 therapies. Multivariate logistic regression was conducted to analyze the association between prognostic factors and disease outcomes. Results & conclusion: Pre-ablation TgAb levels and the changes of TgAb in 6-12 months after the first I-131 therapy were risk factors for disease outcome in patients younger than 55, while extrathyroid extension was a risk factor in patients older than 55. The median TgAb half-life was 7.7 months and the median time for TgAb positivity to become negative was 15.8 months. The dynamics of TgAb within the first year after remnant ablation could predict disease outcome for DTC patients.

引用

页码：1683 / 1692

页数：10

共 38 条

[1] Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens
Chiovato, L
Latrofa, F
Braverman, LE
Pacini, F
Capezzone, M
Masserini, L
Grasso, L
Pinchera, A
[J]. ANNALS OF INTERNAL MEDICINE, 2003, 139 (05) : 346 - 351
[2] Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation
Chung, JK
Park, YJ
Kim, TY
So, Y
Kim, SK
Park, DJ
Lee, DS
Lee, MC
Cho, BY
[J]. CLINICAL ENDOCRINOLOGY, 2002, 57 (02) : 215 - 221
[3] Dewi Ayu Rosemeilia, 2017, World J Nucl Med, V16, P15, DOI 10.4103/1450-1147.174714
[4] The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
Edge, Stephen B.
Compton, Carolyn C.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (06) : 1471 - 1474
[5] Thyroglobulin Autoantibodies as Surrogate Biomarkers in the Management of Patients with Differentiated Thyroid Carcinoma
Feldt-Rasmussen, U.
Verburg, F. A.
Luster, M.
Cupini, C.
Chiovato, L.
Duntas, L.
Elisei, R.
Rimmele, H.
Seregni, E.
Smit, J. W. A.
Theimer, C.
Giovanella, L.
[J]. CURRENT MEDICINAL CHEMISTRY, 2014, 21 (32) : 3687 - 3692
[6] Autoimmunity in differentiated thyroid cancer: Significance and related clinical problems
Feldt-Rasmussen, Ulla
Rasmussen, Ase Krogh
[J]. HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2010, 9 (02): : 109 - 117
[7] Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy
Görges, R
Maniecki, M
Jcntzen, W
Sheu, SNY
Mann, K
Bockisch, A
Janssen, OE
[J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 153 (01) : 49 - 55
[8] 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Haugen, Bryan R.
Alexander, Erik K.
Bible, Keith C.
Doherty, Gerard M.
Mandel, Susan J.
Nikiforov, Yuri E.
Pacini, Furio
Randolph, Gregory W.
Sawka, Anna M.
Schlumberger, Martin
Schuff, Kathryn G.
Sherman, Steven I.
Sosa, Julie Ann
Steward, David L.
Tuttle, R. Michael
Wartofsky, Leonard
[J]. THYROID, 2016, 26 (01) : 1 - 133
[9] Sequential Changes of Serum Antithyroglobulin Antibody Levels Are a Good Predictor of Disease Activity in Thyroglobulin-Negative Patients with Papillary Thyroid Carcinoma
Hsieh, Ching-Jung
Wang, Pei-Wen
[J]. THYROID, 2014, 24 (03) : 488 - 493
[10] Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer
Hu, Tianpeng
Meng, Zhaowei
Zhang, Guizhi
Jia, Qiang
Tan, Jian
Zheng, Wei
Wang, Renfei
Li, Xue
Liu, Na
Zhou, Pingping
Upadhyaya, Arun
[J]. MEDICINE, 2016, 95 (35)

← 1 2 3 4 →